Abstract：
UNASSIGNED: Up-regulating programmed cell death ligand-1(PD-L1) expressed on tumor cells and tumor-infiltrating myeloid cells interacting with up-regulated programmed cell death-1 (PD-1) expressed on tumor-infiltrating lymphoid cells greatly hinder their tumor-inhibiting effect. It is necessary to explore the deep mechanism of this negative effect, so as to find the potential methods to improve the immunotherapy efficiency.
UNASSIGNED: In this study, we found that the PD-1 expression in lung cancer-infiltrating type II innate lymphoid cells (ILC2s) was highly up-regulated, which greatly restrained the activation and function of ILC2s. Furthermore, anti-PD-1 could restore the inhibition and effective cytokine secretion of ILC2s when co-cultured with tumor cells. In vivo studies proved that anti-PD-1 treatment promoted the activation of tumor-infiltrating ILC2s and inhibited the tumor growth of LLC-bearing nude mice.
UNASSIGNED: Our studies demonstrate a new PD-1/PD-L1 axis regulating mechanism on innate immune cells, which provide a useful direction to ILC2s-based immunotherapy to cancer diseases.
UNASSIGNED: In this study, we found that the PD-1 expression in lung cancer-infiltrating type II innate lymphoid cells (ILC2s) was highly up-regulated, which greatly restrained the activation and function of ILC2s. Furthermore, anti-PD-1 could restore the inhibition and effective cytokine secretion of ILC2s when co-cultured with tumor cells. In vivo studies proved that anti-PD-1 treatment promoted the activation of tumor-infiltrating ILC2s and inhibited the tumor growth of LLC-bearing nude mice.
UNASSIGNED: Our studies demonstrate a new PD-1/PD-L1 axis regulating mechanism on innate immune cells, which provide a useful direction to ILC2s-based immunotherapy to cancer diseases.
摘要：
在肿瘤细胞和肿瘤浸润性骨髓细胞上表达的上调程序性细胞死亡配体-1（PD-L1）与在肿瘤浸润性淋巴样细胞上表达的上调程序性细胞死亡-1（PD-1）相互作用极大地阻碍了它们的肿瘤抑制作用。有必要探讨这种负面效应的深层机制,从而寻找提高免疫治疗效率的潜在方法。这里,我们发现PD-1在肺癌浸润型II型固有淋巴细胞（ILC2s）中的表达高度上调，极大地抑制了ILC2s的激活和功能。此外，与肿瘤细胞共培养时，抗PD-1可以恢复ILC2s的抑制作用和有效的细胞因子分泌。体内研究证明，抗PD-1治疗促进了肿瘤浸润ILC2s的激活，并抑制了LLC裸鼠的肿瘤生长。我们的研究证明了一种新的PD-1/PD-L1轴对先天免疫细胞的调节机制，这为基于ILC2s的癌症疾病免疫治疗提供了有益的方向。
